DNA Clinical Trials

62 recruitingLast updated: June 18, 2026

There are 62 actively recruiting dna clinical trials across 15 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1. Top locations include Shanghai, China, Shanghai, Shanghai Municipality, China, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


DNA Trials at a Glance

62 actively recruiting trials for dna are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Not Applicable with 16 trials, with the heaviest enrollment activity in Shanghai, Shanghai, and Beijing. Lead sponsors running dna studies include Fudan University, City of Hope Medical Center, and Centre Hospitalier Universitaire, Amiens.

Browse dna trials by phase

Treatments under study

About DNA Clinical Trials

Looking for clinical trials for DNA? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new DNA trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about DNA clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Not Applicable

Methylated Biomarkers of Smoking as a Selection Tool in Participants for Lung Cancer Screening

Lung Cancer ScreeningEpigeneticsDNA Methylation+2 more
University Hospital, Antwerp1,000 enrolled1 locationNCT07631624
Recruiting
Phase 2

Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation

Immune System DisorderDNA Damage
University of New Mexico100 enrolled1 locationNCT03908736
Recruiting
Not Applicable

The EPIC Study: Exploring Paternal Age and the Influence on Blastocyst Culture

Infertility (IVF Patients)Sperm DNA FragmentationOocyte Competence+2 more
Reproductive Medicine Associates of New Jersey100 enrolled1 locationNCT06629766
Recruiting
Phase 2

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Colorectal, CancerMinimal Residual DiseasectDNA+3 more
M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077
Recruiting

Natural History Study for DNA Repair Disorders

Cockayne SyndromeDNA Repair DisorderXeroderma Pigmentosum+1 more
University of Minnesota40 enrolled1 locationNCT05484570
Recruiting

Study of the Serotype and Genotype of BK Virus in Kidney Transplant Recipients and Their Donors to Identify Individuals at Risk of Nephropathy

Immune responseBK polyomavirusBK Nephropathy+6 more
University Hospital, Grenoble100 enrolled1 locationNCT07347769
Recruiting
Not Applicable

Pesticides and Infertility: Oxidative Stress Via Circulating Cell-free DNA and Gut/Genital Microbiome Signatures in Women With Endometriosis

InfertilityEndometriosisEpigenetics+7 more
Centre Hospitalier Universitaire, Amiens160 enrolled1 locationNCT07471373
Recruiting
Not Applicable

Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity

BiomarkersOral Squamous Cell CarcinomaEpigenetics+3 more
Centre Hospitalier Universitaire, Amiens60 enrolled1 locationNCT05791149
Recruiting
Not Applicable

Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial

Circulating Tumor DNARecurrenceColon Cancer Stage II
UMC Utrecht1,320 enrolled29 locationsNCT06434896
Recruiting
Phase 2

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast CancerTriple-Negative Breast CancerCirculating Tumor DNA+1 more
Dana-Farber Cancer Institute40 enrolled7 locationsNCT04434040
Recruiting
Not Applicable

Danish Vulva Cancer Recurrence Study

SurvivorshipCirculating Tumor DNAVulvar Cancer+6 more
University of Aarhus1,295 enrolled2 locationsNCT06495554
Recruiting
Phase 2

A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer

Colorectal, CancerChemotherapyctDNA
Fudan University100 enrolled1 locationNCT07562490
Recruiting
Phase 2

Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer

Colorectal, CancerChemotherapyctDNA
Fudan University340 enrolled1 locationNCT07562503
Recruiting
Phase 2

Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer

Colorectal, CancerChemotherapyctDNA
Fudan University340 enrolled1 locationNCT07562711
Recruiting
Phase 2

Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer

ctDNAColorectal Cancer (CRC)Adjuvant Chemotherapy
Fudan University80 enrolled1 locationNCT07562659
Recruiting

CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer

Circulating Tumor DNAHigh Grade Serous Ovarian Cancer
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine100 enrolled1 locationNCT05027828
Recruiting

PaCIFiC-CUP Classifies Cancer of Unknown Primary

Unknown Primary TumorsDNA Methylation
Sun Yat-sen University120 enrolled1 locationNCT06140992
Recruiting

NSCLC Liquid Biopsies and Exhaled VOC

Lung CancerCirculating Tumor DNA
St. Joseph's Healthcare Hamilton210 enrolled1 locationNCT06707519
Recruiting

HPV After chemoRadioTherapy

RadiotherapyHPVCervical Cancer Recurrent+1 more
General University Hospital, Prague120 enrolled1 locationNCT07493928
Recruiting
Not Applicable

A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring

Esophageal CancerctDNA
The Central Hospital of Lishui City30 enrolled2 locationsNCT06792786